Generic placeholder image

Current Pharmaceutical Design

Author(s): Qi Lv, Zhang Huiqin, Xiao Na, Liu Chunyan, Shao Zonghong and Wang Huaquan*

DOI: 10.2174/1381612826666200317131940

DownloadDownload PDF Flyer Cite As
Treatment of Severe Aplastic Anemia with Porcine Anti-Human Lymphocyte Globulin

Page: [2661 - 2667] Pages: 7

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Aplastic anemia (AA) is a bone marrow failure syndrome characterized by pancytopenia. Decreased numbers of hematopoietic stem cells and impaired bone marrow microenvironment caused by abnormal immune function describe the major pathogenesis of AA. Hematopoietic stem cell transplantation and immunesuppressive therapy are the first-line treatments for AA. Porcine anti-lymphocyte globulin (p-ALG) is a new product developed in China. Several studies have shown that p-ALG exhibited good therapeutic effects in AA.

Keywords: Anemia, aplastic, porcine anti-human lymphocyte globulin, immunosuppressive, treatment, hematopoietic.

[1]
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016; 172(2): 187-207.
[http://dx.doi.org/10.1111/bjh.13853] [PMID: 26568159]
[2]
Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120(6): 1185-96.
[http://dx.doi.org/10.1182/blood-2011-12-274019] [PMID: 22517900]
[3]
Yang L, Wang H, Shao Z. [Advances in the treatment of severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi 2015; 36(8): 711-5.
[4]
Flynn J, Cox CV, Rizzo S, et al. Direct binding of antithymoctye globulin to haemopoietic progenitor cells in aplastic anaemia. Br J Haematol 2003; 122(2): 289-97.
[http://dx.doi.org/10.1046/j.1365-2141.2003.04400.x] [PMID: 12846899]
[5]
Dubey S, Nityanand S. Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol 2003; 82(8): 496-9.
[http://dx.doi.org/10.1007/s00277-003-0645-x] [PMID: 12783210]
[6]
Saunthararajah Y, Nakamura R, Nam J-M, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100(5): 1570-4.
[http://dx.doi.org/10.1182/blood.V100.5.1570.h81702001570_1570_1574] [PMID: 12176872]
[7]
Shao W, Tian D, Liu C, Sun X, Zhang X. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol 2000; 71(4): 350-2.
[PMID: 10905054]
[8]
Kapustin SI, Popova TI, Lyshchov AA, Imyanitov EN, Blinov MN, Abdulkadyrov KM. HLA-DR4-Ala74 beta is associated with risk and poor outcome of severe aplastic anemia. Ann Hematol 2001; 80(2): 66-71.
[http://dx.doi.org/10.1007/s002770000234] [PMID: 11261326]
[9]
Oguz FS, Yalman N, Diler AS, Oguz R, Anak S, Dorak MT. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica 2002; 87(7): 772-4.
[PMID: 12091130]
[10]
Thota S, Patel BJ, Sadaps M, et al. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. Br J Haematol 2018; 183(1): 133-6.
[http://dx.doi.org/10.1111/bjh.14907] [PMID: 28905372]
[11]
Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 2001; 115(4): 1023-31.
[http://dx.doi.org/10.1046/j.1365-2141.2001.03212.x] [PMID: 11843845]
[12]
Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336(19): 1365-72.
[http://dx.doi.org/10.1056/NEJM199705083361906] [PMID: 9134878]
[13]
Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood 2006; 107(10): 3983-91.
[http://dx.doi.org/10.1182/blood-2005-10-4201] [PMID: 16434488]
[14]
Smith JNP, Kanwar VS, MacNamara KC. Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Front Immunol 2016; 7: 330-0.
[http://dx.doi.org/10.3389/fimmu.2016.00330] [PMID: 27621733]
[15]
Liu CY, Fu R, Wang HQ, et al. Fas/FasL in the immune pathogenesis of severe aplastic anemia. Genet Mol Res 2014; 13(2): 4083-8.
[http://dx.doi.org/10.4238/2014.May.30.3] [PMID: 24938700]
[16]
Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007; 110(5): 1603-6.
[http://dx.doi.org/10.1182/blood-2007-01-066258] [PMID: 17463169]
[17]
Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood 2016; 128(9): 1193-205.
[http://dx.doi.org/10.1182/blood-2016-03-703702] [PMID: 27281795]
[18]
Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365(5): 430-8.
[http://dx.doi.org/10.1056/NEJMoa1103975] [PMID: 21812672]
[19]
Yan L, Fu R, Liu H, et al. Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. Cell Immunol 2015; 296(2): 95-105.
[http://dx.doi.org/10.1016/j.cellimm.2015.04.001] [PMID: 25906694]
[20]
Babushok DV, Perdigones N, Perin JC, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet 2015; 208(4): 115-28.
[http://dx.doi.org/10.1016/j.cancergen.2015.01.007] [PMID: 25800665]
[21]
Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373(1): 35-47.
[http://dx.doi.org/10.1056/NEJMoa1414799] [PMID: 26132940]
[22]
Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood 2016; 128(3): 337-47.
[http://dx.doi.org/10.1182/blood-2016-01-636381] [PMID: 27121470]
[23]
Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011; 118(25): 6601-9.
[http://dx.doi.org/10.1182/blood-2011-07-365189] [PMID: 21963603]
[24]
Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014; 124(17): 2698-704.
[http://dx.doi.org/10.1182/blood-2014-05-574889] [PMID: 25139356]
[25]
Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood 2003; 101(7): 2833-41.
[http://dx.doi.org/10.1182/blood-2002-07-2095] [PMID: 12424196]
[26]
Shen W, Clemente MJ, Hosono N, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest 2014; 124(10): 4529-38.
[http://dx.doi.org/10.1172/JCI74747] [PMID: 25244093]
[27]
Hanaoka N, Kawaguchi T, Horikawa K, Nagakura S, Mitsuya H, Nakakuma H. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. Blood 2006; 107(3): 1184-91.
[http://dx.doi.org/10.1182/blood-2005-03-1337] [PMID: 16195329]
[28]
Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017; 129(11): 1428-36.
[http://dx.doi.org/10.1182/blood-2016-08-693481] [PMID: 28096088]
[29]
Dufour C, Pillon M, Sociè G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol 2015; 169(4): 565-73.
[http://dx.doi.org/10.1111/bjh.13297] [PMID: 25683884]
[30]
Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica 2014; 99(12): 1784-91.
[http://dx.doi.org/10.3324/haematol.2014.109355] [PMID: 25193958]
[31]
Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014; 99(10): 1574-81.
[http://dx.doi.org/10.3324/haematol.2014.106096] [PMID: 25085353]
[32]
Young NS. Aplastic Anemia. N Engl J Med 2018; 379(17): 1643-56.
[http://dx.doi.org/10.1056/NEJMra1413485] [PMID: 30354958]
[33]
Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110(4): 1397-400.
[http://dx.doi.org/10.1182/blood-2007-03-081596] [PMID: 17475907]
[34]
Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118(9): 2618-21.
[http://dx.doi.org/10.1182/blood-2011-05-354001] [PMID: 21677312]
[35]
Konopacki J, Porcher R, Robin M, et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica 2012; 97(5): 710-6.
[http://dx.doi.org/10.3324/haematol.2011.050096] [PMID: 22180425]
[36]
Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147(1): 43-70.
[http://dx.doi.org/10.1111/j.1365-2141.2009.07842.x] [PMID: 19673883]
[37]
Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012; 119(23): 5391-6.
[http://dx.doi.org/10.1182/blood-2012-02-407684] [PMID: 22544699]
[38]
Atta E H, Dias D S P, Marra V L N, et al. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study 89(9): 851-9.
[39]
Afable MG II, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011; 96(9): 1269-75.
[http://dx.doi.org/10.3324/haematol.2011.042622] [PMID: 21606164]
[40]
Vallejo C, Montesinos P, Polo M, et al. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Ann Hematol 2015; 94(6): 947-54.
[http://dx.doi.org/10.1007/s00277-015-2305-3] [PMID: 25672649]
[41]
Sakamoto T, Obara N, Kurita N, et al. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol 2013; 98(3): 319-22.
[http://dx.doi.org/10.1007/s12185-013-1418-5] [PMID: 23963878]
[42]
Suzuki T, Kobayashi H, Kawasaki Y, et al. Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol 2016; 104(4): 446-53.
[http://dx.doi.org/10.1007/s12185-016-2046-7] [PMID: 27338268]
[43]
Zhang HQ, Wang HQ, Shao ZH. [Progress in the treatment of severe aplastic anemia with porcine anti- human lymphocyte globulin]. Zhonghua Xue Ye Xue Za Zhi 2016; 37(10): 926-8.
[44]
Bonnefoy-Bérard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51(3): 669-73.
[http://dx.doi.org/10.1097/00007890-199103000-00024] [PMID: 2006524]
[45]
Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57(5): 685-94.
[http://dx.doi.org/10.1097/00007890-199403150-00010] [PMID: 7908150]
[46]
Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59(8): 1194-200.
[http://dx.doi.org/10.1097/00007890-199504270-00020] [PMID: 7732566]
[47]
Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med 1985; 312(5): 257-65.
[http://dx.doi.org/10.1056/NEJM198501313120501] [PMID: 2981406]
[48]
Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91(7): 2360-8.
[http://dx.doi.org/10.1182/blood.V91.7.2360] [PMID: 9516135]
[49]
Kawano Y, Nissen C, Gratwohl A, Speck B. Immunostimulatory effects of different antilymphocyte globulin preparations: a possible clue to their clinical effect. Br J Haematol 1988; 68(1): 115-9.
[http://dx.doi.org/10.1111/j.1365-2141.1988.tb04188.x] [PMID: 3257882]
[50]
Taniguchi Y, Frickhofen N, Raghavachar A, Digel W, Heimpel H. Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol 1990; 44(4): 244-51.
[http://dx.doi.org/10.1111/j.1600-0609.1990.tb00387.x] [PMID: 2188853]
[51]
Hunter RF, Mold NG, Mitchell RB, Huang AT. Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. Proc Natl Acad Sci USA 1985; 82(14): 4823-7.
[http://dx.doi.org/10.1073/pnas.82.14.4823] [PMID: 3875092]
[52]
Huang AT, Mold NG, Zhang SF. Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc Natl Acad Sci USA 1987; 84(16): 5942-6.
[http://dx.doi.org/10.1073/pnas.84.16.5942] [PMID: 3112777]
[53]
Killick SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 2000; 108(3): 582-91.
[http://dx.doi.org/10.1046/j.1365-2141.2000.01853.x] [PMID: 10759717]
[54]
Bing H, Siyi Y, Wei Z, et al. The use of anti-human T lymphocyte porcine immunoglobulin and cyclosporine a to treat patients with acquired severe aplastic anemia. Acta Haematol 2010; 124(4): 245-50.
[http://dx.doi.org/10.1159/000321790] [PMID: 21099214]
[55]
Han B, Yan S-Y, Zou N, et al. [Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi 2011; 32(4): 241-4.
[56]
Chen M, Liu C, Zhuang J, et al. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. Eur J Haematol 2016; 96(3): 291-6.
[http://dx.doi.org/10.1111/ejh.12590] [PMID: 25996247]
[57]
Wei J, Huang Z, Guo J, et al. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis. Ann Hematol 2015; 94(6): 955-62.
[http://dx.doi.org/10.1007/s00277-015-2308-0] [PMID: 25666078]
[58]
Liu L, Ding L, Hao L, et al. Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immuno globulin as a first-line treatment against acquired severe aplastic anemia. Ann Hematol 2015; 94(5): 729-37.
[http://dx.doi.org/10.1007/s00277-014-2279-6] [PMID: 25604721]
[59]
Zhang X, Liu L, Zhao G, et al. [Porcine anti-human lymphocyte immunoglobulin plus cydosporine in the treatment of severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi 2014; 35(5): 451-3.
[60]
Ma X, Wang J, Zhang W, et al. Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study. Eur J Haematol 2016; 96(3): 260-8.
[http://dx.doi.org/10.1111/ejh.12584] [PMID: 25966958]
[61]
Yang Y, Zhang W, Cao X, et al. Clinical study of combination of pig antithymocyte globulin and cyclosporine A as first-line therapy for adult severe aplastic anemia. J Clin Intern Med.. 2015; (4): 249-51.
[62]
Yang N, Ma X-R, Zhang H, et al. Therapeutic effects of porcine versus rabbit antithymocyte globulins for treatment of severe aplastic anemia Nan fang yi ke da xue xue bao = J Southern Med Univ 2016; 36(3): 303-08.
[63]
Chen Y-H, Huang X-J, Xu L-P, et al. [A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors]. Zhonghua Nei Ke Za Zhi 2006; 45(8): 624-7.
[PMID: 17074143]
[64]
Ye B-D, Zhang X, Shao K-D, et al. Combined use of Chinese medicine with allogeneic hematopoietic stem cell transplantation for severe aplastic anemia patients. Chin J Integr Med 2014; 20(12): 903-9.
[http://dx.doi.org/10.1007/s11655-014-2026-9] [PMID: 25428338]
[65]
Tang X-D, Liu F, Li L, et al. Analysis of the prognostic factors of very severe aplastic anemia treated with Chinese Kidney-invigorating drugs in combination with anti-lymphocyte globulin or anti-thymocyte globulin. Chin J Integr Med 2012; 18(1): 40-5.
[http://dx.doi.org/10.1007/s11655-011-0874-0] [PMID: 22160947]
[66]
Liu L-P, Chen X-J, Yang W-Y, et al. Predicting response to porcine antilymphocyte globulin plus cyclosporine A in children with acquired severe aplastic anemia. Pediatr Res 2019; 86(3): 360-4.
[http://dx.doi.org/10.1038/s41390-019-0437-1] [PMID: 31112993]
[67]
Li JP, Yang WR, Li Y, et al. [Antithymocyte/Antilymphocyte globulin plus cyclosporine A therapy for the treatment of older patients with severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi 2016; 37(7): 607-10.
[68]
Cui Q, Sha P, Chen H, et al. Modified immunosuppressive therapy with porcine antilymphocyte globulin plus delayed cyclosporine A in children with severe aplastic anemia. Int J Hematol 2018; 107(1): 64-8.
[http://dx.doi.org/10.1007/s12185-017-2321-2] [PMID: 28900860]
[69]
Chen X, Wei J, Huang Y, et al. Effect of antithymocyte globulin source on outcomes of hla-matched sibling allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia. Biology of blood and marrow transplantation. J American Society Blood Marrow Transplantation 2018; 24(1): 86-90.
[70]
Chen M, Liu C, Qiao X, Zhou D, Zhuang J, Han B. Comparative study of porcine anti-human lymphocyte immunoglobulin and rabbit anti-human thymocyte immunoglobulin as a first-line treatment of acquired severe aplastic anemia. Leuk Res 2018; 65: 55-60.
[http://dx.doi.org/10.1016/j.leukres.2018.01.001] [PMID: 29306655]
[71]
Tichelli A, Gratwohl A, Nissen C, Speck B. Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994; 12(3-4): 167-75.
[http://dx.doi.org/10.3109/10428199409059587] [PMID: 8167549]
[72]
Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329(16): 1152-7.
[http://dx.doi.org/10.1056/NEJM199310143291603] [PMID: 8377778]